# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
SNK01, a cryopreserved autologous non-genetically modified NK cell product, is able to effectively reduce α-synuclein (α-syn) p...
NKGen Biotech shares are trading higher by 32.5% Thursday morning. The company announced it will present new SNK01 biomarker da...
NKGN: 88% | NKGen Biotech Will Present New Biomarker Data On SNK01 In Alzheimer's Disease During A Poster Presentation At T...
NKGen will present data on SNK01's ability to reduce α-synuclein in Alzheimer's patients, which is significant given th...